September was Sickle Cell Awareness Month, designated by the U.S. Congress to increase awareness about sickle cell disease (SCD) and help boost research and development targeting the disease.
Theris Medical, Inc., a TauTona Group biopharmaceutical company developing life-changing solutions for wound care, announces today the enrollment of their first patient in the company’s Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment (D-SCOUT) clinical trial (NCT 04058197). The trial will investigate the company’s Deferoxamine Intradermal Drug Patch (DIDP), for the topical treatment of Sickle Cell Leg Ulcers (SCUs) in support of its Orphan Drug Designation awarded in March of 2019.
Enforcement Report - Week of October 11, 2017
Walgreens Infusion Services, Ongoing Class III recall of Deferoxamine various strengths in normal saline because of Lack of sterility assurance.